ClearPoint Neuro, Inc.: ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026

ClearPoint Neuro, Inc. (NASDAQ:CLPT) said it will release its 2026 second-quarter results on August 3, 2026 after the market close. The company will host a live conference call the same day at 4:30 p.m. ET, with a replay available until September 2, 2026. No financial figures were provided.

Original reporting
Published Jul 21, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 21, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CLPT
Neutral
medium confidence
Mentioned
$CLPT
Relevance
4/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$CLPTNeutralMed
01

Why it matters

The key new information is the confirmed date and after-hours timing for the 2026 second-quarter results release and the associated earnings call schedule.

02

Market read

Provides a concrete calendar catalyst for traders to manage earnings-week risk and liquidity around the after-hours print.

03

What to watch

Traders should watch for any pre-announcement materials (8-K, investor deck) or changes in biotech partner activity that could affect ClearPoint Neuro’s device and services demand, which are not mentioned here.

Relevance 4/10Novelty 3/10Timing: Ahead of the Aug 3 after-hours 2026 Q2 earnings release and 4:30 p.m. ET call.

Background

ClearPoint Neuro is a device, cell, and gene therapy-enabling company focused on navigation for brain and spine, with FDA-cleared and CE-marked technology.

Company-level read

Ticker impact

$CLPTNeutralMedium confidence
Context

ClearPoint Neuro (CLPT) will release 2026 Q2 results on Aug 3 after the close, with a live call at 4:30 p.m. ET.

Expected impact

Likely volatility around the Aug 3 after-hours earnings release, with direction dependent on Q2 results and any updated outlook.

Evidence & confidence

The article discloses only the timing of the Q2 results and conference call, not the numbers or guidance. Timing alone can drive trading activity, but magnitude/direction is unknown.

Market effects

Limited read-through to the broader device and CNS delivery space because no clinical, regulatory, or financial datapoints are provided.

Primarily US-focused trading around an after-hours earnings event.

Low, as the release timing is company-specific and no international regulatory or partnership updates are disclosed.

Counterpoint

Because the release date is already foreseeable for many companies, the incremental trading edge may be small unless traders expect a notable surprise in results or guidance.

Key entities

  • ClearPoint Neuro, Inc.

    NASDAQ-listed company (CLPT) announcing the Aug 3 after-market Q2 2026 results release and conference call details.

Related articles

$CLPTHighAI 8/10

ClearPoint Neuro stock tumbles on uniQure trial setback

ClearPoint Neuro (CLPT) shares dropped 24% after partner uniQure (QURE) reported disappointing trial data for its Huntington's disease treatment, AMT-130. The therapy failed to meet primary clinical measures, raising concerns about future revenue for ClearPoint Neuro, which provides delivery hardware and software for the treatment.

$CLPTMed

ClearPoint Neuro Reports Second Quarter 2026 Results

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2026 Results Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA, August 3, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a globa

$FMSMed

Fresenius Medical Care names Korangy as new chief executive

Fresenius Medical Care (FME) named Shervin J Korangy as its new CEO and management board chair, effective October 12. Korangy brings healthcare and life sciences leadership experience, previously serving as CEO of BVI Medical. Fresenius Medical Care operates 3,513 dialysis clinics worldwide. Shares have traded between €34.57 and €47.86 over the past year, closing at €37.42 on Wednesday.